^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr del(17p)

    Related tests:
    Apply
    Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2018
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    TP53 • CD4
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)
    Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE) (NCT04008706)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/17/2019
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    TP53 • CD20 • IGH • CD5 • FCER2
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma (NCT04579523)
    Phase 1
    Fred Hutchinson Cancer Center
    Not yet recruiting
    Last update posted :
    02/12/2025
    Initiation :
    05/01/2025
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    Chr del(17p)
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235)
    Phase 1
    Noah Merin
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    07/18/2018
    Primary completion :
    11/07/2021
    Completion :
    11/01/2031
    MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B
    |
    Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression
    |
    Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)
    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (NCT01163357)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/28/2011
    Primary completion :
    07/20/2019
    Completion :
    12/31/2024
    HLA-DRB1
    |
    Chr del(17p)
    |
    bortezomib • sirolimus • melphalan • fludarabine IV
    Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients (NCT05529069)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    01/25/2023
    Primary completion :
    04/28/2027
    Completion :
    04/28/2027
    TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2
    |
    TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (NCT01203722)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    09/01/2010
    Primary completion :
    09/01/2025
    Completion :
    12/01/2025
    FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)
    |
    cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
    ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (NCT03441958)
    Phase 1/2
    Ciusss de L'Est de l'Île de Montréal
    Active, not recruiting
    Last update posted :
    02/08/2024
    Initiation :
    03/07/2018
    Primary completion :
    10/28/2023
    Completion :
    10/17/2025
    CD34
    |
    Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As
    |
    cyclophosphamide • melphalan • Zemcelpro (dorocubicel)
    T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia (NCT03531736)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    11/30/2023
    Initiation :
    05/09/2018
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    TP53 • FLT3 • ABL1 • BCR • RUNX1 • ASXL1
    |
    TP53 mutation • Chr del(17p) • FLT3 mutation • RUNX1 mutation • ASXL1 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients (NCT02308280)
    Phase 2
    Maisonneuve-Rosemont Hospital
    Completed
    Last update posted :
    10/19/2023
    Initiation :
    11/01/2014
    Primary completion :
    09/27/2018
    Completion :
    09/27/2023
    HLA-B • HLA-C
    |
    Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As
    |
    bortezomib • melphalan
    Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (NCT03342144)
    Phase N/A
    AbbVie
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    12/04/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    TP53
    |
    TP53 mutation • Chr del(17p) • TP53 mutation + Chr del(17p)
    |
    Venclexta (venetoclax)